Patents by Inventor Pingda Ren

Pingda Ren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted quinazolines as kinase inhibitors
    Patent number: 9359349
    Abstract: The present invention provides compounds of Formula I that modulate PI3 kinase activity and methods of treatment of diseases and conditions associated with PI3 kinase activity.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: June 7, 2016
    Assignee: INTELLIKINE LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson
  • PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
    Publication number: 20160152619
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 2, 2016
    Inventors: Pingda REN, Michael MARTIN, Paul ISBESTER, Benjamin S. LANE, Jason KROPP
  • Benzoxazole kinase inhibitors and methods of use
    Patent number: 9345706
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: May 24, 2016
    Assignee: Intellikine, LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan
  • INHIBITORS OF KRAS G12C MUTANT PROTEINS
    Publication number: 20160108019
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein R1, R2, R3a, R3b, R4a, R4b, G1, G2, L, m1, m2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Application
    Filed: September 25, 2015
    Publication date: April 21, 2016
    Inventors: Liansheng Li, Jun Feng, Pingda Ren, Yi Liu
  • Heterocyclic compounds and uses thereof
    Patent number: 9315505
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the isoquinolone entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: April 19, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Troy Edward Wilson
  • Combination of Kinase Inhibitors and Uses Thereof
    Publication number: 20160089371
    Abstract: The present invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase a and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth. The present invention also provides a pharmaceutical kit effective for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject.
    Type: Application
    Filed: March 12, 2014
    Publication date: March 31, 2016
    Inventors: Yi Liu, Pingda Ren, Katayoun Jessen, Xin Guo, Christian Rommel, Troy Edward Wilson
  • Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
    Patent number: 9295673
    Abstract: The present invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase ? and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: March 29, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Katayoun Jessen, Xin Guo, Christian Rommel, Troy Edward Wilson
  • Heterocyclic kinase inhibitors
    Patent number: 9296742
    Abstract: Provided herein are compounds of formula (I-A), (I-B), (I-C), or (I-D), pharmaceutical compositions comprising the compounds, and methods of use thereof. The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: March 29, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson
  • Processes for preparing isoquinolinones and solid forms of isoquinolinones
    Patent number: 9290497
    Abstract: Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: March 22, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Pingda Ren, Michael Martin, Paul Isbester, Benjamin S. Lane, Jason Kropp
  • Heterocyclic compounds and uses thereof
    Patent number: 9255108
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: February 9, 2016
    Assignee: Infinity Pharmaceuticals, Inc.
    Inventors: Alfredo C. Castro, Katrina Chan, Catherine A. Evans, Somarajannair Janardanannair, Andre Lescarbeau, Liansheng Li, Tao Liu, Yi Liu, Pingda Ren, Daniel A. Snyder, Martin R. Tremblay
  • IRREVERSIBLE COVALENT INHIBITORS OF THE GTPASE K-RAS G12C
    Publication number: 20160031898
    Abstract: Irreversible inhibitors of K-Ras, H-Ras or N-ras protein comprising a G12C mutation are provided. Also disclosed are methods to regulate the activity of K-Ras, H-Ras or N-ras protein comprising G12C mutation and methods to disease mediated by K-Ras, H-Ras or N-ras G12C.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Jun Feng
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
    Publication number: 20160031886
    Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 4, 2016
    Inventors: Pingda REN, Yi LIU, Troy Edward WILSON, Liansheng LI, Katrina CHAN, Christian ROMMEL
  • KINASE INHIBITORS AND METHODS OF USE
    Publication number: 20160024099
    Abstract: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.
    Type: Application
    Filed: July 7, 2015
    Publication date: January 28, 2016
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson
  • CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION
    Publication number: 20160016957
    Abstract: Chemical compounds that modulate kinase activity, including PI3 kinase activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.
    Type: Application
    Filed: September 29, 2015
    Publication date: January 21, 2016
    Inventors: Pingda REN, Yi LIU, Liansheng LI, Katrina CHAN, Alfredo C. CASTRO, Catherine A. EVANS
  • MTOR MODULATORS AND USES THEREOF
    Publication number: 20160000789
    Abstract: The present invention provides methods and compositions for selective modulation of certain protein kinases, and especially mTor complexes. The methods and compositions are particularly useful in inhibiting mTor selectively for therapeutic applications.
    Type: Application
    Filed: June 5, 2015
    Publication date: January 7, 2016
    Inventors: Kevan M. Shokat, David Fruman, Pingda Ren, Troy Edward Wilson, Liansheng Li, Andrew Hsieh, Morris Feldman, Beth Apsel, Yi Liu, Christian Rommel, Katrina Chan, Davide Ruggero, David Pearce, Matthew Janes
  • Covalent inhibitors of Kras G12C
    Patent number: 9227978
    Abstract: Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 5, 2016
    Assignee: Araxes Pharma LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Jun Feng, Tao Wu
  • Certain chemical entities, compositions and methods
    Patent number: 9216982
    Abstract: Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: December 22, 2015
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
  • Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof
    Patent number: 9206182
    Abstract: Substituted isoquinolin-1(2H)-one compounds that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: December 8, 2015
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Troy Edward Wilson, Liansheng Li, Katrina Chan, Christian Rommel
  • Heterocyclic Compounds and Uses Thereof
    Publication number: 20150322064
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: July 16, 2015
    Publication date: November 12, 2015
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20150320727
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: June 2, 2015
    Publication date: November 12, 2015
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell